{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:58:17Z","timestamp":1792090697760,"version":"4.4.0"},"reference-count":20,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Standardized Care Pathway (SCP) for patients presenting with macroscopic haematuria was introduced in Sweden in 2015. In contrast to neighbouring countries, the Swedish model includes all patients with macroscopic haematuria above the age of 50, notwithstanding obvious causes. The aim of this study was to characterize the patients referred within the SCP and the presence of acute cystitis.\nAll patients admitted to two regional hospitals in 2023, under the terms of SCP macroscopic haematuria, were included. Patient data were collected retrospectively regarding age, sex, symptoms of cystitis and cause of haematuria.\nThe study included 782 patients. The median age was 70 years and half were women. In 89 cases, a urinary tract cancer was found (11%) and 74 (9%) had bladder cancer. The cancer-positive group was significantly older (median 75 years) and 76% were men. Half of patients (51%) had symptoms of acute cystitis on referral. This was significantly associated with the absence of bladder cancer, but only in the age groups 50\u201369, where no case was found among patients with symptoms of cystitis. In the age groups above, 22 cancer-positive patients (30% of all bladder cancer cases) had symptoms of cystitis.\nThe Swedish SCP macroscopic haematuria targets younger female patients unproportionally, in comparison to where cancer is likely found. Neither symptoms of cystitis, nor positive urine cultures exclude bladder cancer in elderly, but clearly in the age groups 50\u201369. If excluding the latter from the SCP, a 28% reduction of examined patients can be achieved with a negligible risk of missing cancer.<\/jats:p>","DOI":"10.2340\/sju.v60.45026","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:33:11Z","timestamp":1766061191000},"page":"238-243","source":"Crossref","is-referenced-by-count":1,"title":["Association between symptoms of acute cystitis and findings of bladder cancer in the Swedish standardized pathway for macroscopic haematuria"],"prefix":"10.2340","volume":"60","author":[{"given":"Gustaf","family":"Starlander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Shkair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Wagenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Bl\u00e4ckberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"136552","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","DOI":"10.3322\/caac.21492"},{"key":"136553","doi-asserted-by":"crossref","unstructured":"Malmstr\u00f6m PU, G\u00e5rdmark T, Sherif A, Strock V, et al. Incidence, survival and mortality trends of bladder cancer in Sweden 1997\u20132016. Scand J Urol. 2019;53(4):193\u20139. https:\/\/doi.org\/10.1080\/21681805.2019.1632380","DOI":"10.1080\/21681805.2019.1632380"},{"key":"136554","doi-asserted-by":"crossref","unstructured":"Shapley M, Mansell G, Jordan JL, et al. Positive predictive values of >\/=5% in primary care for cancer: systematic review. Br J Gen Pract. 2010;60(578):e366\u201377. https:\/\/doi.org\/10.3399\/bjgp10X515412","DOI":"10.3399\/bjgp10X515412"},{"key":"136555","doi-asserted-by":"crossref","unstructured":"Malmstr\u00f6m PU, Skaaheim Haug E, Bostr\u00f6m PJ, et al. Progress towards a Nordic standard for the investigation of hematuria: 2019. Scand J Urol. 2019;53(1):1\u20136. https:\/\/doi.org\/10.1080\/21681805.2018.1555187","DOI":"10.1080\/21681805.2018.1555187"},{"key":"136556","doi-asserted-by":"crossref","unstructured":"Holm\u00e4ng S, Hedelin H. Standardized care pathway for bladder cancer in Sweden. So far lots of pain but little gain. Scand J Urol. 2022;56(3):233\u20134. https:\/\/doi.org\/10.1080\/21681805.2022.2078876","DOI":"10.1080\/21681805.2022.2078876"},{"key":"136557","doi-asserted-by":"crossref","unstructured":"Nilbert M, Bl\u00e4ckberg M, Ceberg J, et al. Diagnostic pathway efficacy for urinary tract cancer: population-based outcome of standardized evaluation for macroscopic haematuria. Scand J Urol. 2018;52(4):237\u201343. https:\/\/doi.org\/10.1080\/21681805.2018.1498124","DOI":"10.1080\/21681805.2018.1498124"},{"key":"136558","doi-asserted-by":"crossref","unstructured":"Vasdev N, Thorpe AC. Should the presence of a culture positive urinary tract infection exclude patients from rapid evaluation hematuria protocols? Urol Oncol. 2013;31(6):909\u201313. https:\/\/doi.org\/10.1016\/j.urolonc.2011.07.016","DOI":"10.1016\/j.urolonc.2011.07.016"},{"key":"136559","doi-asserted-by":"crossref","unstructured":"Luu T, Albarillo FS. Asymptomatic bacteriuria: prevalence, diagnosis, management, and current antimicrobial stewardship implementations. Am J Med. 2022;135(8):e236\u201344. https:\/\/doi.org\/10.1016\/j.amjmed.2022.03.015","DOI":"10.1016\/j.amjmed.2022.03.015"},{"key":"136560","doi-asserted-by":"crossref","unstructured":"Bollestad M, Vik I, Grude N, et al. Bacteriology in uncomplicated urinary tract infections in Norwegian general practice from 2001\u20132015. BJGP Open. 2018;1(4):bjgpopen17X101145. https:\/\/doi.org\/10.3399\/bjgpopen17X101145","DOI":"10.3399\/bjgpopen17X101145"},{"key":"136561","doi-asserted-by":"crossref","unstructured":"Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509\u201315. https:\/\/doi.org\/10.1001\/jamainternmed.2018.4204","DOI":"10.1001\/jamainternmed.2018.4204"},{"key":"136562","doi-asserted-by":"crossref","unstructured":"Vik I, Bollestad M, Grude N, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med. 2018;15(5):e1002569. https:\/\/doi.org\/10.1371\/journal.pmed.1002569","DOI":"10.1371\/journal.pmed.1002569"},{"key":"136563","doi-asserted-by":"crossref","unstructured":"Abuhasanein S, Jahnson S, Kj\u00f6lhede H. Shortened time to diagnosis for patients suspected of urinary bladder cancer managed in a standardized care pathway was associated with an improvement in tumour characteristics. BJUI Compass. 2024;5(2):261\u20138. https:\/\/doi.org\/10.1002\/bco2.301","DOI":"10.1002\/bco2.301"},{"key":"136564","doi-asserted-by":"crossref","unstructured":"Abuhasanein S, Jahnson S, Aljabery F, et al. Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience. Scand J Urol. 2022;56(3):227\u201332. https:\/\/doi.org\/10.1080\/21681805.2022.2058605","DOI":"10.1080\/21681805.2022.2058605"},{"key":"136565","doi-asserted-by":"crossref","unstructured":"Elmussareh M, Young M, Ordell Sundelin M, et al. Outcomes of haematuria referrals: two-year data from a single large university hospital in Denmark. Scand J Urol. 2017;51(4):282\u20139. https:\/\/doi.org\/10.1080\/21681805.2017.1310759","DOI":"10.1080\/21681805.2017.1310759"},{"key":"136566","doi-asserted-by":"crossref","unstructured":"Boman H, Hedelin H, Holm\u00e4ng S. The results of routine evaluation of adult patients with haematuria analysed according to referral form information with 2-year follow-up. Scand J Urol Nephrol. 2001;35(6):497\u2013501. https:\/\/doi.org\/10.1080\/003655901753367613","DOI":"10.1080\/003655901753367613"},{"key":"136567","doi-asserted-by":"crossref","unstructured":"Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306\u201314; discussion 14\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2006.09.019","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"136568","doi-asserted-by":"crossref","unstructured":"Secher MS, Hyldgaard J, Jensen JB. The association between gender, stage and prognosis in bladder cancer patients undergoing radical cystectomy. Scand J Urol. 2023;57(1\u20136):10\u20134. https:\/\/doi.org\/10.1080\/21681805.2023.2166103","DOI":"10.1080\/21681805.2023.2166103"},{"key":"136569","doi-asserted-by":"crossref","unstructured":"Malmstr\u00f6m PU. Time to abandon testing for microscopic haematuria in adults? BMJ. 2003;326(7393):813\u20135. https:\/\/doi.org\/10.1136\/bmj.326.7393.813","DOI":"10.1136\/bmj.326.7393.813"},{"key":"136570","doi-asserted-by":"crossref","unstructured":"Malmstr\u00f6m PU, Truls G. Abandoning testing for asymptomatic microscopic haematuria in Sweden \u2013 a long-term follow-up. Scand J Urol. 2023;58:109\u201314. https:\/\/doi.org\/10.2340\/sju.v58.11142","DOI":"10.2340\/sju.v58.11142"},{"key":"136571","doi-asserted-by":"crossref","unstructured":"Lara J, Brunson A, Keegan TH, et al. Determinants of survival for adolescents and young adults with urothelial bladder cancer: results from the California Cancer Registry. J Urol. 2016;196(5):1378\u201382. https:\/\/doi.org\/10.1016\/j.juro.2016.05.082","DOI":"10.1016\/j.juro.2016.05.082"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45026\/52347","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45026\/52347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:33:14Z","timestamp":1766061194000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/45026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.2340\/sju.v60.45026","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}